Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma

Haematologica. 2006 Jun;91(6):862-3.

Abstract

We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Recurrence
  • Survival Analysis
  • Thalidomide / administration & dosage
  • Treatment Outcome

Substances

  • Thalidomide
  • Dexamethasone
  • Cyclophosphamide